{"id":10862,"date":"2026-02-17T19:57:40","date_gmt":"2026-02-17T19:57:40","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/10862\/"},"modified":"2026-02-17T19:57:40","modified_gmt":"2026-02-17T19:57:40","slug":"roche-secures-ce-mark-for-kidney-disease-algorithm","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/10862\/","title":{"rendered":"Roche secures CE mark for kidney disease algorithm"},"content":{"rendered":"<p>Roche Holdings AG received CE-mark for the Kidney Klinrisk algorithm, an AI-based tool developed in collaboration with Klinrisk Inc. to stratify risk and assess the progressive decline in kidney function. The software will help clinicians to make more informed decisions when accessing adults with chronic kidney disease as well as individuals with diabetes or hypertension who are at elevated risk of kidney function decline.<\/p>\n<p><a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/85-medical-technology\" rel=\"nofollow noopener\" target=\"_blank\">Medical technology<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/402-regulatory\" rel=\"nofollow noopener\" target=\"_blank\">Regulatory<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/325-diagnostics\" rel=\"nofollow noopener\" target=\"_blank\">Diagnostics<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/326-artificial-intelligence\" rel=\"nofollow noopener\" target=\"_blank\">Artificial intelligence<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/265-urology\" rel=\"nofollow noopener\" target=\"_blank\">Urology<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/396-europe\" rel=\"nofollow noopener\" target=\"_blank\">Europe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Roche Holdings AG received CE-mark for the Kidney Klinrisk algorithm, an AI-based tool developed in collaboration with Klinrisk&hellip;\n","protected":false},"author":2,"featured_media":10863,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[2252,225,4176,8295,8296,8298,4010,1176,197,8294,8299,8300,8297,4180,134,6399,4295,8301],"class_list":["post-10862","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-ai","tag-artificial-intelligence","tag-bioworld-medtech","tag-cachexia","tag-cancer-induced-cachexia","tag-chronic-kidney-disease","tag-ckd","tag-diagnostics","tag-europe","tag-helmholtz-diabetes-center","tag-kidney-klinrisk-algorithm","tag-klinrisk-inc","tag-pen-x-acip","tag-regulatory","tag-roche","tag-roche-holdings-ag","tag-software","tag-urology"],"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/10862","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=10862"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/10862\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/10863"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=10862"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=10862"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=10862"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}